PBA:NYSEPembina Pipeline Corp. Analysis
Data as of 2026-05-23 - not real-time
$49.58
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Pembina Pipeline is trading at $49.58, comfortably above its 20‑day ($46.96) and 50‑day ($45.30) moving averages and near the $50.10 resistance level. The stock shows bullish momentum with a bullish MACD crossover, but the RSI of 75 signals an overbought condition, and the Fear & Greed Index is at an "Extreme Greed" 91.6, suggesting heightened market optimism. Recent earnings releases highlighted a stronger‑than‑expected first‑quarter adjusted EBITDA and an upward revision of full‑year guidance, which helped lift sentiment, yet Citi downgraded the stock to neutral, citing valuation concerns.
Fundamentally, the market price is far above the DCF‑derived fair value of $7.74 and the analyst median target of $41.74, implying a substantial overvaluation. The company carries a high debt‑to‑equity ratio of 82% and a dividend payout ratio exceeding 100%, raising questions about dividend sustainability despite a 4.19% yield. With a 30‑day volatility of ~20%, a low beta, and solid operating margins, the risk profile is mixed, prompting a cautious stance on the stock's near‑term upside while recognizing its long‑term cash‑flow stability.
Fundamentally, the market price is far above the DCF‑derived fair value of $7.74 and the analyst median target of $41.74, implying a substantial overvaluation. The company carries a high debt‑to‑equity ratio of 82% and a dividend payout ratio exceeding 100%, raising questions about dividend sustainability despite a 4.19% yield. With a 30‑day volatility of ~20%, a low beta, and solid operating margins, the risk profile is mixed, prompting a cautious stance on the stock's near‑term upside while recognizing its long‑term cash‑flow stability.
Market Outlook
Short Term
< 1 yearCautious
Model confidence: 7/10
Key Factors
- RSI in overbought territory
- Price approaching resistance with limited upside
- High valuation relative to DCF and analyst target
Medium Term
1–3 yearsNeutral
Model confidence: 6/10
Key Factors
- Persistent overvaluation despite solid cash flow
- Dividend payout above 100% and high leverage
- Potential price correction toward target price
Long Term
> 3 yearsPositive
Model confidence: 7/10
Key Factors
- Stable midstream contract revenues
- Share repurchase program and potential debt reduction
- Attractive yield if dividend becomes sustainable at lower price
Key Metrics & Analysis
Financial Health
Revenue Growth-7.70%
Profit Margin22.23%
P/E Ratio25.7
ROE9.81%
ROA4.28%
Debt/Equity82.35
P/B Ratio2.6
Op. Cash Flow$2.8B
Free Cash Flow$1.4B
Industry P/E21.6
Technical Analysis
TrendBullish
RSI75.0
Support$43.27
Resistance$50.10
MA 20$46.96
MA 50$45.30
MA 200$40.91
MACDBullish
VolumeIncreasing
Fear & Greed Index91.61
Valuation
Fair Value$7.74
Target Price$41.74
Upside/Downside-15.82%
GradeOvervalued
TypeBlend
Dividend Yield4.19%
Risk Assessment
Beta-0.07
Volatility20.55%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.